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Background: This systematic review and meta-analysis seeks to determine whether 
corticosteroids are of bene!cial use in cardiac surgery.
Methods: A database search was conducted using PubMed and EMBASE for 
randomised controlled trials (RCTs) comparing steroid use with a placebo in adults 
undergoing cardiac surgery, between 1990-2018. The quality of each study was 
assessed using the Jadad scoring system, and only double-blind studies with a score ≥3 
were included. 53 RCTs were identi!ed, and 14 were considered suitable for analysis.
Results: The corticosteroids used in the studies were methylprednisolone (57.1%), 
dexamethasone (35.7%), and hydrocortisone (7.1%). Steroid use signi!cantly 
reduced incidence of infection [relative risk (RR) 0.83; 95% con!dence interval 
(CI) 0.84-1.06; P<0.0001; I2=75%] and length of hospital stay [mean di#erence 
-0.36; 95% CI -0.5 – -0.21; P<0.00001; I2=88%]. Incidence of new atrial !brillation 
was signi!cantly reduced [RR 0.94; 95% CI 0.89-1.06; P=0.03; I2=0%], but this 
outcome was no longer signi!cant when only large studies were included [RR 0.96; 
95% CI 0.90-1.01; P=0.13; I2=0%]. Myocardial infarction was more frequent with 
steroid administration [RR 1.17; 95% CI 1.07-1.38; P=0.008; I2=0%], and there was 
no signi!cant di#erence in mortality [RR 0.87; 95% CI 0.70-1.07; P=0.14; I2=0%].
Conclusions: A$er analysing the data from RCTs of 12,999 patients, perioperative 
corticosteroid administration was found to signi!cantly reduce the risk of 
postoperative infection and length of hospital stay but increased the risk of myocardial 
infarction. More large trials need to be conducted in order to adequately assess the 
potential bene!ts of corticosteroid use in cardiac surgery.
Oliver Darwin 
University of Nottingham 
Address for Correspondence: 
Oliver Darwin
University of Nottingham
Medical School
Nottingham, NG7 2UH
Email: mzyod2@nottingham.ac.uk
ORCID: 0000-0001-5548-9198
No con!icts of interest to declare.
Accepted for publication: 09.06.20
The British Student Doctor, 2020;4(2):7-17
doi: 10.18573/bsdj.148
Original Research
Ѷ0v7fĺou]ĺh
$!	&$ 
Cardiac surgery is a common surgical procedure, with an average 
of 49 coronary artery bypass gra$s alone per 100,000 people 
in the EU each year, (1) and cardiopulmonary bypass (CPB) is 
utilised in most cardiac surgery procedures. CPB use producing a 
systemic in%ammatory response has been thoroughly reported in 
the literature, and the mechanism has been linked to the exposure 
of blood to hypothermia, non-physiological %ow, and foreign 
surfaces, (2) resulting in the activation of platelets, neutrophils, and 
cytokine cascades. (3) This in%ammatory reaction is exacerbated 
by ischaemia-reperfusion injury when removing the patient from 
CPB. (3) This systemic in%ammatory response may contribute 
to postoperative complications of cardiac surgery including 
atrial !brillation, (3) myocardial dysfunction, (4) multiple organ 
dysfunction, (5) and mortality. This is because in%ammatory 
mediators are known to have cardiodepressive e#ects. (6)
Steroids have been shown to reduce the body’s in%ammatory 
response to CPB, (2,7) but their e#ect on clinical outcomes is not 
yet clear. The 2017 EACTS guidelines (32) on the use of steroids 
indicate that a previous 2008 meta-analysis has shown that steroids 
reduced postoperative atrial !brillation, postoperative bleeding, 
and duration of hospital stay, but produced an increased rate of 
myocardial infarction. More recently, two larger trials have been 
carried out, the Steroids In caRdiac Surgery (SIRS) trial (7) and 
the Dexamethasone in Cardiac Surgery (DECS) study, (8) and thus 
the author thought it relevant to the !eld, and a good exercise as a 
medical student, to revisit the data. 
As such, this systematic review and meta-analysis aims to determine 
whether prophylactic corticosteroid administration is e#ective in 
reducing morbidity and mortality in patients undergoing on-pump 
cardiac surgery.
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RCT identi!cation
A database search was conducted for published randomised 
controlled trials (RCTs) comparing corticosteroid use with a 
placebo in adults undergoing cardiac surgery involving CPB, 
between 1990-2018. PubMed and EMBASE databases were 
searched. The search terms included: ‘cardiac surgery, open heart 
surgery, coronary artery bypass gra$, CABG, valve surgery, aortic 
valve, mitral valve, heart valve, CPB, cardiopulmonary bypass, 
pre-operative, intraoperative, and prophylactic’, in combination 
with ‘steroid, corticosteroid, glucocorticoid, hydrocortisone, 
dexamethasone, and methylprednisolone’. The references of 
included studies were then reviewed for other potentially relevant 
studies. 
RCT selection
Exclusion criteria were then applied to the identi!ed RCTs, and 
trials were excluded if: 1) there was a lack of a randomised double-
blind trial design, 2) there was a lack of data regarding clinical 
outcomes, 3) there was a lack of a placebo group, or 4) if there were 
other treatments confounding the corticosteroids. This meant that 
53 RCTs were selected from those initially identi!ed. 
The quality of each study was then assessed using the Jadad scoring 
system, (9) mainly focussing on patient randomisation and adequacy 
of follow-up. As previously advised in the literature, (10) only 
studies with a score of at least 3 were included. Following this, 14 
studies ful!lled the criteria and were included in this meta-analysis. 
The search strategy is shown in Figure 1.
Figure 1 
Flow diagram of trial selection
Study Design
Summary characteristics of the RCTs that were included in this 
meta-analysis are shown in Table 1.
Table 1 
Summary characteristics of included RCTs
Ten trials included patients undergoing isolated coronary artery 
bypass gra$, (8,11-17,19,21) and four trials included all patients 
undergoing CPB. (7,18,20,22) The vast majority (96.0%) of 
patients belonged to four trials. (13,19,20,22) All trials involved 
steroids being administered preoperatively or intraoperatively, 
and the steroids used in the trials were methylprednisolone, 
(7,8,11,12,14,15,17,22) dexamethasone, (13,16,19-21) or 
hydrocortisone (18) (Table 2). Di#ering doses of corticosteroids 
were given in each trial, as there is no e#ective guideline for dosage 
in preoperative or intraoperative steroid administration, and these 
are outlined below. 
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Table 2  
Comparison of steroids and dosages in included RCTs
Eleven studies looked at mortality, (7,8,11,13,14,16-20,22) nine at 
the incidence of myocardial infarction (MI), (7,8,11,13,14,19-22) 
twelve at the hospital length of stay, (7,8,11,12,14-18,20-22) ten at 
the incidence of new-onset AF, (7,8,11,14,16,18-22) and seven at 
the incidence of infection. (7,16,17,19-22)
De!nitions
Mortality was considered as all-cause mortality occurring before 
hospital discharge, or up to thirty days postoperatively. Infection 
was considered as relevant if it occurred before hospital discharge, 
or up to thirty days postoperatively. MI or new-onset AF were 
considered if it occurred before hospital discharge, or up to thirty 
days postoperatively. Length of hospital stay was measured in days.
Statistical analysis
Clinical outcome data were extracted from each trial, and the 
outcomes for the patients receiving steroids were compared with 
patients in the control groups. Discrete outcomes, i.e. mortality, 
infection, AF and MI, were reported as relative risks (RRs) with a 
95% CI. Continuous outcomes, i.e. length of hospital stay, were 
reported as a mean di#erence (MD) with a 95% CI. The outcomes 
were compared using the !xed-e#ects model. The so$ware used 
to perform the statistical calculations was RevMan (version 5.3, 
Cochrane Collaboration, Oxford). The I2 test was used to assess 
statistical heterogeneity, and a I2 >25 was considered as signi!cant 
heterogeneity. A sensitivity analysis was conducted using only large 
trials (>1000 patients), to assess the validity of the results.
!"&$"
Outcomes
Mortality in the steroid group was 189 out of 6425 patients (2.9%) 
compared to 218 out of 6404 patients (3.4%) in the control group, 
which indicates no signi!cant di#erence [RR 0.87; 95% CI 0.70-
1.07; p=0.14; I2=0%] (Figure 2). 
Myocardial infarction incidence in the steroid group was 532 out of 
6421 patients (8.3%) compared to 452 out of 6407 patients (7%) 
in the control group, which is a signi!cant increase in the steroid 
group [RR 1.17; 95% CI 1.07-1.38; p=0.008; I2=0%] (Figure 3).
New-onset atrial !brillation incidence in the steroid group was 
1671 out of 6451 patients (25.9%) compared to 1778 out of 6439 
patients (27.6%) in the control group, which represents a signi!cant 
reduction in the steroid group [RR 0.94; 95% CI 0.89-1.06; 
p=0.03; I2=0%] (Figure 4).
The incidence of infection in the steroid group was 686 out of 6183 
patients (11.1%) compared to 832 out of 6201 patients (13.4%) in 
the control group, which represents a signi!cant reduction with 
steroid use [RR 0.83; 95% CI 0.84-1.06; p<0.0001; I2=75%] 
(Figure 5).
There was statistically signi!cant decrease in length of hospital stay 
in the steroid group compared with the control group of 0.36 days 
[MD -0.36; 95% CI -0.5 – -0.21; p<0.00001; I2=88%] (Figure 6).
Sensitivity analysis
When the sensitivity analysis was carried out, including only 
large trials (>1000 patients), only the outcome of new-onset atrial 
!brillation was changed, with the e#ect of steroids becoming non-
signi!cant when compared to the control group [RR 0.96; 95% CI 
0.90-1.01; p=0.13; I2=0%] (Figure 7). All statistical analysis of the 
outcomes was heavily in%uenced by the largest trial in the analysis 
(21), with the weighting ranging from 47.6% for new-onset AF to 
88.0% for MI.
Heterogeneity analysis
Signi!cant heterogeneity (I2 >25) was encountered for length of 
hospital stay and incidence of infection. Surgery type did not a#ect 
the outcomes.
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Figure 2 
Forest plot for mortality - the size of the 
box correlates with the weight of the 
study estimate
Figure 4  
Forest plot for atrial !brillation - 
the size of the box correlates with 
the weight of the study estimate
Figure 3 
Forest plot for myocardial infarction 
- the size of the box correlates with 
the weight of the study estimate
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Figure 5
Forest plot for incidence of infection - 
the size of the box correlates with the 
weight of the study estimate
Figure 7  
Forest plot for atrial !brillation: 
only including large trials (>1000 
patients) - the size of the box 
correlates with the weight of the 
study estimate
 
Figure 6  
Forest plot for length of hospital 
stay - the size of the box correlates 
with the weight of the study 
estimate
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This systematic review and meta-analysis suggests that 
preoperative or intraoperative administration of corticosteroids 
results in a signi!cant reduction in the incidence of infection 
and the length of hospital stay a$er cardiac surgery, although 
these results were associated with signi!cant heterogeneity. 
The reduced incidence of infection following corticosteroid 
administration is counter-intuitive, as steroid-induced immune 
suppression is widely considered to potentially increase the risk 
of postoperative infection. Thus, this outcome may be a result of 
spurious diagnosis of systemic in%ammatory response as opposed 
to infection, or vice versa. However, several studies have noted a 
correlation between preoperative C-reactive protein concentration 
(and thus in%ammatory status) and incidence of postoperative 
infection, (23,24) with a possible mechanism being that rate of 
bacterial growth has been shown to increase in the presence of 
proin%ammatory cytokines in vitro. (25)
Although length of hospital stay was signi!cantly decreased in the 
steroid group, this author questions whether a reduction in length 
of stay of 0.36 days is of clinical signi!cance.
These data also suggest that prophylactic steroid administration 
does not signi!cantly a#ect mortality when compared to control 
groups but is associated with an increased incidence of myocardial 
infarction. This increase in myocardial infarction may possibly 
be due to the e#ect of increased insulin resistance a#orded by 
corticosteroids, blocking glucose from entering cardiac myocytes 
and furthering ischaemic injury. 
The increase in rates of myocardial infarction is di&cult to align 
with no increase in mortality, as this is a patient population 
in which myocardial injury is associated with poorer clinical 
outcomes. This discrepancy may be due to the di&culty in de!ning 
myocardial injury a$er cardiac surgery, as all patients experience 
release of cardiac biomarkers. Evidence for the thresholds of 
clinically signi!cant cardiac biomarkers following cardiac surgery 
is not available, and therefore a robust and well-de!ned approach 
needs to be taken. Whitlock et al (22) used systematic monitoring 
of CK-MB to diagnose myocardial injury, and consequently found 
an increase in both myocardial infarction and associated mortality, 
suggesting that the discrepancy in these rates may be due to study 
design.
The data show a statistically signi!cant decrease in new-onset 
atrial !brillation, but this signi!cance disappears when only larger 
trials are included in the analysis, suggesting that the smaller 
studies are producing this result. In%ammation of myocardial tissue 
following CPB and cardiac surgery has been theorised to be the 
cause of new-onset AF postoperatively, (26,27) hence the rationale 
for the inclusion of new-onset AF in the RCTs in this analysis. 
However, when only large trials were included, this meta-analysis 
demonstrated that prophylactic steroid administration has no e#ect 
on the incidence of new-onset AF, suggesting that the pathogenesis 
of AF following CPB is more complex than a result of myocardial 
in%ammation. 
Strengths and weaknesses
Previous meta-analyses have been conducted on the use of steroids 
in cardiac surgery, (28,29) but this is the !rst to include only high 
quality RCTs (as demonstrated by the Jadad scoring system). As a 
result, this meta-analysis had a reduced number of RCTs included, 
but the quality of the analysis and resulting outcomes was higher 
with a mean Jadad score of 3.9.
An additional strength of this systematic review and meta-analysis 
is the diligent methodology of trial identi!cation, data extraction, 
and outcome analysis, resulting in a high degree of con!dence in 
the results. The search was comprehensive, utilising two large trial 
databases for published data, and the vast majority of patient groups 
included in the RCTs represented all CPB procedures (93.1%), 
leading to a high degree of generalisability of outcomes.
This systematic review and meta-analysis does, however, have 
several limitations. The majority of the data came from four 
individual RCTs, meaning they had a very signi!cant e#ect 
weighting on the outcomes measured. A greater number of 
large trials to draw data from would improve the reliability of 
these results. Furthermore, there was signi!cant heterogeneity 
and variability between trials regarding the steroids and dosages 
used, meaning that clinical and methodological variability was 
introduced into the results. A subgroup analysis was conducted 
that found there was no statistical signi!cance in results between 
di#erent types of steroid (p=0.16), and thus a !xed-e#ects model 
was suitable for the analysis. A random-e#ects model could have 
been used to address the heterogeneity in dosage between studies, 
but as all dosages were within therapeutic range, the author felt that 
this was not suitable. Were a bene!t to be found in corticosteroid 
administration during this review, a random-e#ects model could 
have been used to determine if steroid dosage a#ected the clinical 
outcomes.
Additionally, this meta-analysis was carried out by a medical 
student and began as a training review before being adapted 
into a full systematic review. As such, this work was not able to 
be prospectively registered with the PROSPERO register of 
systematic reviews, (30) and did not bene!t from the presence 
of additional reviewers, against standard PRISMA-P guidelines. 
(31) The author acknowledges the possibility of introducing 
methodological errors, unnecessary bias, and a reduction in 
transparency that these decisions a#ord this work. However, the 
author believes that the robustness of the protocols and validity of 
the analysis warrant consideration of the results. Were similar work 
to be repeated, the author would ensure the PRISMA-P protocols 
for systematic review were adhered to.
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This systematic review represents a thorough and comprehensive 
assessment of the safety and e&cacy of prophylactic corticosteroid 
use in cardiac surgery. This review suggests that steroid use 
decreases the incidence of postoperative infection, reduces the 
length of hospital stay, increases the risk of myocardial infarction, 
has no statistically signi!cant e#ect on postoperative mortality, 
and signi!cantly reduces the incidence of new-onset AF (although 
this result should be taken with caution, as analysis of large trials 
showed no signi!cant di#erence). Two large RCTs accounted for 
the majority weighting of these results, and further large trials are 
needed in order to con!rm or refute these !ndings with greater 
certainty.
Given the increased risk of myocardial infarction, the dubious result 
of reduction in postoperative infection, and the trivial reduction 
in length of hospital stay, this meta-analysis has found that the 
EACTS guidance that routine use of prophylactic steroids is not 
indicated for patients undergoing cardiac surgery remains true and 
prudent advice.
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